Targeted Radiolabeled Compounds in Glioma Therapy

Area of Science:

• Neuro-oncology
• Radiopharmaceutical therapy
• Molecular imaging and targeted therapy

Background:

• Malignant gliomas (WHO grades II-IV) are aggressive brain tumors with poor prognoses.
• Infiltrative growth and lack of clear tumor borders present significant therapeutic challenges.
• Standard treatments (surgery, radiotherapy, chemotherapy) have shown limited improvement in patient survival.

Purpose of the Study:

• To evaluate substance P-based targeted therapy for malignant gliomas.
• To investigate the efficacy of radiolabeled substance P analogues for glioma treatment.
• To explore novel therapeutic strategies for the invasive tumor cell front.

Main Methods:

• Development of substance P analogues conjugated to chelators (DOTA/DOTAGA).
• Labeling with alpha- or beta-particle emitting radionuclides for targeted therapy.
• Local injection of radiopharmaceuticals into tumors or resection cavities in clinical studies.

Main Results:

• Substance P receptor overexpression is consistent across glioma grades II-IV.
• Radiolabeled substance P-based therapy shows favorable comparison to standard treatments.
• Bismuth-213 (Bi-213) labeling is promising due to high linear energy transfer and short range.

Conclusions:

• Substance P-based targeted glioma therapy is a promising strategy.
• Further research needed to improve compound stability and delivery systems for optimal distribution.
• Targeting the infiltrative tumor zone is critical for improving glioma patient outcomes.